What to do when anticoagulation fails to achieve recanalization in symptomatic acute splanchnic vein thrombosis without cirrhosis

This protocol addresses a specific next-line decision point: a patient with symptomatic acute splanchnic vein thrombosis, no liver cirrhosis, and no active bleeding, in whom standard anticoagulant therapy has not achieved the primary treatment goal.

Clinical scenario

Symptomatic acute splanchnic vein thrombosis in a non-cirrhotic patient with no signs of active bleeding.

Prior treatment — goal not reached

First-line therapy with DOACs — or LMWH / VKAs in patients who cannot receive DOACs — targeted the highest possible vessel recanalization. This protocol is the next step when that goal has not been met despite adequate anticoagulant therapy.

Next-line approach (partial)

For very carefully selected patients at specialized centers, a thrombolytic approach may be considered — the full eligibility criteria, route, and clinical context are detailed in the structured protocol.

Goal: achieve the highest possible vessel recanalization

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jth.14836

In non-cirrhotic patients with symptomatic acute splanchnic vein thrombosis who have no signs of active bleeding, we suggest full therapeutic dose of DOACs, and consider LMWH and VKAs with INR range of 2.0-3.0 in patients who cannot tolerate or have contraindications for DOACs.

In patients with symptomatic acute splanchnic vein thrombosis we recommend against the routine use of systemic or catheter-directed thrombolysis. We suggest considering the use of thrombolysis in specialized centers for very selected patients such as those with mesenteric or extensive splanchnic vein thrombosis and signs of intestinal ischemia, or those whose conditions deteriorate despite adequate anticoagulant therapy.

Treatment of occlusive or non-occlusive acute splanchnic vein thrombosis aims to prevent intestinal infarction or ischemia, and achieve the highest possible vessel recanalization to reduce splanchnic hypertension and bleeding risk.

View source ↗